A recent study suggests that metabolites may be a biomarker for disease activity in patients with rheumatoid arthritis (RA). For the first time, researchers identified serum metabolomic profiles and 16 clinical parameters that serve as a reasonably predictive model for a patient’s therapeutic response to biological treatment of RA, specifically TNF-α inhibitor therapy…
Statins have anti-inflammatory/immunomodulatory effects that may be useful in preventing rheumatoid arthritis (RA), but previous observational studies about the risk of RA with statin use yielded conflicting results. In this large population-based study, high-intensity statin treatment was associated with a 23% reduced risk of RA when compared with low-intensity statin treatment. This is the largest study on the association of statins with RA risk to date, and the first to assess the effect of relative statin strength…
Obesity has an established systemic inflammatory component. Could that be a trigger for the inflammation seen in rheumatoid arthritis (RA) and other rheumatic diseases? Although there is no direct scientific evidence, both mechanistic and epidemiologic clues do give some intriguing suggestions of a possible link. “At first, we thought that fat was involved only in…
Established wisdom holds that patients with rheumatoid arthritis (RA) will fare better if their disease is diagnosed as early as possible, and treatments with disease-modifying drugs are started before inflammation can do more damage to joints and tissue. Usually, early diagnosis means spotting the clinical signs of disease, but new research tells us more about…
LONDON—Research continues to advance in understanding the causes, prediction and management of the stages of early arthritis before full-blown clinical disease, and an expert highlighted some of the latest of these encouraging findings at the Annual Congress of the European League Against Rheumatism (EULAR) 2016. Many of the genetic and environmental risk factors are known,…
LONDON—New research shows that the synovial compartment appears to have a special role in the chronic nature of rheumatoid arthritis (RA), providing refuge for plasma cells and giving them an ideal environment in which to produce antibodies against citrullinated protein antigens (ACPA). The findings were presented at the Annual Congress of the European League Against…
According to a new study, patients with aggressive rheumatoid arthritis (RA) have lower levels of non-esterified fatty acids, which coincide with an enhanced Th1 response. Researchers suggest that lower EPA and DHA at the onset of RA may exacerbate inflammation, and fatty acids may become a novel therapeutic target for the disease…
Survey results released earlier this year found that communication difficulties exist between patients and their rheumatologists for many reasons—possibly resulting in more disease activity despite advances in RA treatments. Here are tips for communicating with your patients and helping them be more proactive in their care…
LONDON—Josef Smolen, MD, chair of rheumatology at the University of Vienna and former president of the European League Against Rheumatism (EULAR), expressed a “personal disappointment” in the development of useful biomarkers in the treatment of rheumatoid arthritis (RA). Even though a good portion of his life’s work has been researching biomarkers to help with targeting…
LONDON—From optimizing responses to methotrexate, to the efficacy of biologics, to the need for imaging in assessing remission, the literature, as ever, has been lively with explorations of pressing topics in the treatment and management of rheumatoid arthritis. Josef Smolen, MD, chair of rheumatology at the Medical University of Vienna, reviewed many of the highlights…